Memorial Page for Harald zur Hausen

Harald zur Hausen (born 11 March 1936 in Gelsenkirchen; died 28 May 2023 in Heidelberg) was a German physician and virologist. He showed that specific human papillomaviruses can cause cancer, especially cervical cancer. For this discovery he received half of the Nobel Prize in Physiology or Medicine in 2008. His work changed cancer research because it turned a contested hypothesis into a path toward prevention: HPV vaccination.

Medicine and virology

Zur Hausen studied medicine and received his doctorate in 1960. After working in Düsseldorf, he moved to the Virus Laboratories at the Children's Hospital in Philadelphia. There he worked in a setting where viruses, cellular change and cancer development were studied together. In 1969 he completed his habilitation in Würzburg, followed by professorships in Erlangen-Nuremberg and Freiburg. From early on, his research focused on whether infections could be involved in the development of human tumors.

The HPV hypothesis

In the 1970s zur Hausen challenged a common assumption of the time. Many researchers suspected herpes simplex viruses as a cause of cervical cancer. Zur Hausen instead considered human papillomaviruses decisive. The idea was difficult to prove because there was no single easily detectable virus in every sample. His team searched for genetic traces of different HPV types and used methods that could detect imperfect matches between viral DNA and tumor tissue.

HPV16 and HPV18

The breakthrough came in the early 1980s. Zur Hausen's group identified HPV16 and later HPV18 in cervical cancer tissue samples. This helped explain how certain high-risk types of the virus enter cells, integrate parts of their genetic material and contribute to cancer development. The Nobel Committee honored this research as the discovery of human papillomaviruses causing cervical cancer. Basic research had become a medical possibility: targeted prevention against a common cancer.

German Cancer Research Center

From 1983 to 2003 Harald zur Hausen led the German Cancer Research Center in Heidelberg. Under his leadership, the DKFZ grew in international standing and strengthened links between basic research and clinical application. Zur Hausen was not only a laboratory scientist. He understood research as a long, testable path from an idea to evidence and then to use. That attitude also shaped the route toward HPV vaccines, which were approved in Europe from 2006.

Nobel Prize and impact

On 6 October 2008 it was announced that Harald zur Hausen would receive half of the Nobel Prize in Physiology or Medicine. The other half went to Françoise Barré-Sinoussi and Luc Montagnier for the discovery of HIV. Zur Hausen's award stood for research whose benefit reached far beyond a laboratory result. It helped clarify the connection between infection and cancer, and it laid the scientific foundation for vaccination programs against HPV-related cancers.

Later years and legacy

Even after his years as DKFZ director, zur Hausen remained scientifically active and publicly engaged, especially on cancer prevention and higher HPV vaccination rates. He died in Heidelberg on 28 May 2023. His importance lies in the persistence with which he followed an uncomfortable question until it became reliable evidence. His legacy reaches beyond the Nobel Prize: HPV-related cancers can now be targeted for prevention because a viral origin was recognized.